Generation of recombinant therapeutic proteins involves the use of Chinese hamster ovary cells as one of the workhorses for complex protein production. This process requires screening large numbers of transfected cells to identify single clones that have high protein production and drug-specific quality attributes. Traditionally, this process was limited by manual operation; however, high-throughput screening methods and automation have made this process more efficient. Implementation of high-throughput screening and automation within bioprocess development have led to increased screening capacity, higher product yields, reductions in manual operation, reduction in human error and shorter development time lines. This review outlines the high-throughput methodologies and technologies currently used for clone screening, selection and evaluation in bioprocess development.
Automated high-throughput clone screening & imaging
The process of developing recombinant Chinese hamster ovary (CHO) cell lines for the expression of therapeutic proteins begins with introducing a DNA plasmid-borne gene of interest to be expressed and a selection marker into a host cell line by transfection (e.g., lipidbased, electroporation, etc.) [1] [2] [3] . Successfully transfected cells express both the gene of interest and the selection marker gene; importantly, the selection marker gene product allows survival of cells within media containing selective pressure. This selection process occurs over a few weeks to ensure that the plasmid-borne gene of interest and selection marker have been integrated into the host cell genome in a stable manner. This integration event is random and the expression of the gene of interest is heavily influenced by the site of integration in the CHO host cell genome [1] . Due to the nature of this integration event, it is advantageous to screen a large number of the transfected cells to increase the probability of selecting the highest producing cells.
Before high-throughput automated methods were implemented in cell line development, the most widely used screening method for the clonality of transfected cells was limiting-dilution cloning. In this method, tranfected cells are seeded into 96-well microtiter plates at cell concentrations less than one cell per well in order to achieve a single cell per well by manual microscopic evaluation. This method is time consuming and labor intensive, while yielding fewer single colonies that are able to be screened for protein production.
This colony screening selection process is one of the main bottlenecks in generating a high-producing cell lines, because these processes are time consuming and labor intensive [4] . In most cases the number of high producing clones detected is directly proportional to the number of clones screened [5] . Over the years, there have been various highthroughput methods developed to reduce man power and process timelines, as well as increase the overall efficiency of screening. Common methods include: flow cytometry based cloning methods [2, [5] [6] [7] [8] [9] , automated future science group Review Keil colony picking systems [7, [10] [11] [12] that increase the recovery of high-producing transfected cells and the use of fully automated robotic selection systems that increase throughput and efficiency across multiple steps in the clone selection process [4, 13] .
Flow cytometry based screening methods are one of the more popular methods used when producing recombinant therapeutic proteins in mammalian host cells. Implementation of this method also provides an increased probability that each well of the microtiter plate receives a single-cell, therefore there is a higher probability that colonies arising from those single cells will be clonal. In addition, deposition of a singlecell into each well of the microtiter plate significantly increases the screening power of the fluorescenceactivated cell sorting (FACS) method when compared with limiting dilution cloning, where only a portion of the seeded wells have a high statistical probability of containing a single cell. To further increase the specificity for selecting high producing cells during FACS cloning, detection antibodies against the protein of interest (in most cases this would be an IgG) are used to label the high-producing cells. The detection antibody is conjugated to a fluorochrome that can be detected when performing flow cytometry [2, [5] [6] [7] [8] [9] , and after incubation with the antibody, single cells with the highest fluorescent intensity can be preferentially sorted into microtiter plates. This method increases the likelihood of isolating the highest producers from the transfection pool. Furthermore, it has been shown to increase in the production levels of selected clones three-to four-fold post screening process and scaleup [9] . As an alternative to fluorescently labeling high producing cells, integration of a fluorescent marker along with the gene of interest has also been proven to be a highly successful way to screen for high producing cells [7, 14] . However, the production of this additional fluorescent marker protein could potentially raise concerns with regulatory agencies. Downstream purification methods or recombinant DNA technologies are two potential methods of removing this additional protein post screening.
Until recently, visualization of cells in microtiter plates to confirm cell-positive wells and monoclonality was highly labor intensive and tedious. With the advent of automated microscopic imaging systems and object recognition software packages the ability to screen increased numbers of microtiter plates for single-cell deposition has greatly increased. After cloning, microtiter plates are loaded onto the imaging system and high-resolution images of each well of the microtiter plate are taken on the day of cell deposition. Subsequently, time-lapsed microscopic imaging of the microtiter plates occurs every few days in order to monitor the outgrowth from a single cell into a fully expanded colony, as can be seen in Figure 1 [2, 4] . The documentation of each microtiter plate is not only critical in the identification of the location of each of the wells containing colonies, but it is also critical for the confirmation of the cell line monoclonality. This is also important for assurance of cell line stability and product quality consistency, and is critical when filing for approval with the regulatory authorities.
The following are a sampling of some of the more widely used imaging systems available: Clone Select Imager™ (www.moleculardevices.com) [15] , Cellavista™ (www.synentec-bioservices.com), Celligo S™ Imaging Cell Cytometer (www.nexcelom.com), Cell Metric CLD (www.soletim.com). In general, all of these benchtop automation systems require limited adaptation and evaluation to be integrated into an existing cell line development workflow. These automated microscope systems can also be integrated with robotic arms and cell culture incubators to allow for a continuous automated workflow for microtiter plate visualization.
Automated colony picking systems offer an alternative method of cloning transfected cells to flow cytometry based cloning methods. The Molecular Devices ClonePix FL™ (www.moleculardevices.com) system functions on the premise of transfected cells being seeded into semi-solid media. As these single cells expand into a colonies, they also secrete the protein of interest into the semi-solid media. The semi-solid media contains a fluorescently conjugated capture antibody that binds the secreted protein product, and upon binding, fluorescently labels the secreted proteins and forms a complex. This complex formation can be detected using the on-board imaging system and colony identification software within the ClonePixFL™ system. The system is capable of capturing images in both white and fluorescent light, which allows the user to overlay the two images. The protein/detection antibody complexes are visualized as fluorescent halos surrounding the colonies, which are expressing the highest levels of the protein of interest (Figure 2 ). Once the highest producing colonies have been identified, the software relaysthe exact coordinates of the respective colonies within the plates to the liquid handling arm and picks and transfers those c olonies to the scale-up vessel [7, [10] [11] [12] 16] .
In addition to the screening platforms described above, large-scale fully automated robotic platforms for screening and cell culture maintenance have also been developed. These systems contain multiple integrated modules to perform a variety of activities; an example of those modules are: incubators, shakers, liquid handlers, automated microscopes, refrigerators, culture vessel handling robots and flow cytometers [17, 18] . 
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One such system is the Cello™ robotic system designed by Sartorius/TAP Biosystems (www.tapbiosystems.com). This system is implemented immediately after transfection of the host cells and seeding of the microtiter plates with the transfected cells. Once the plates are loaded onto this robotic platform, the system is then capable of monitoring the colony growth from a single cell to a full grown colony using the integrated automated microscopic imaging system. The system software will then identify these colonies, harvest them into 24-well plates, and then further expand the cultures into 6-well plates [4] . This type of fully integrated platform provides the advantages of increased throughput and reduction in manual labor. Many pharmaceutical companies are investing in these types of systems; however, the capital investment to purchase one of these systems is quite significant. Additionally, highly trained and dedicated personnel are required to operate and maintain a large robotic platform of this nature.
Automated high-throughput clone selection
Within bioprocess development the use of liquid handlers has become widespread and they are now integral components to many workflows. With regard to cell line screening and selection, liquid handling systems allow the scientists to screen and manipulate large numbers of clones with ease. These systems are highly adaptable to multiple workflows through the integration of various components such as plate washers, shakers, incubators, vacuum filtration and many other functions. Some of the more popular liquid handlers used in bioprocess development areas are: Tecan™ Evo series liquid handlers (www.tecan.com), Hamilton™ Microlab Star line liquid handlers (www.hamiltoncompany.com) and Beckman Coulter BioMek™ liquid handlers (www.beckmancoulter.com).
Utilizing the high-throughput cloning methods described above, very large numbers of potential product producing colonies are identified in microti- future science group
Review Keil ter plates after microscopic imaging. These datasets generated on the imaging system can be transformed and exported to a liquid handling system. The system will then identify the wells within the microtiter plates that contain the desired cell growth, sample them and the dilute those samples into assay plate [4, 17, 19] . High-throughput automated immunoassays for product concentration determination have been developed on liquid handling platforms, and can process thousands of samples in a few hours. Traditionally, manual ELISA assays have been used in bioprocess development for product concentration determination, however, these assays are time consuming and laborious. Through the adaptation of ELISA assay protocols onto liquid handling platforms and the use of highdensity plate formats (96-well, 384-well, etc.), there have been significant increases in capacity as well as a reduction of human error utilizing these platforms. ELISA assays in general are cost effective to perform (on a per sample basis), easy to automate, adaptable to various proteins (in terms of analyte and detection), provides good accuracy and reproducible.
Benchtop automation solutions for product concentration determination have become increasingly popular High-throughput screening & automation approaches for the development of recombinant therapeutic proteins Review for cell line development applications due to their compact design and their ease of use. These systems have been designed as a 'walk-up' operation where the scientist requires limited training in order to operate these systems. In contrast, while the liquid handling systems offer much more flexibility, versatility and are able to process many more samples, they do require the scientist to have a higher level of training in order to execute the workflows on those particular systems. The Gyros Gyrolab™ workstation (www.gyros.com) and the ForteBio Octet™ (www.fortebio.com) system are two benchtop automation systems that provide fast, efficient and accurate data for production concentration determination.
The Gyros Gyrolab™ workstation is a microfluidicbased platform. It has been shown to be an efficient and easy to adapt alternative to the traditional immunoassay methods for product concentration determination. The system has the ability to perform fully automated reagent and sample transfer into microfluidic compact discs via its integrated liquid handling arm located within the unit. Each compact disc contains a series parallel solid-phase microstructures composed of a 15 nl streptavidin column. Microfluidic capillaries built into these compact discs deliver the reagents and samples to the streptavidin columns. Biotinylated capture reagents are loaded onto the bead bed by rotating the discs at specific speeds so as the fluids can move through the microfluidic capillaries and across the packed column at the appropriate velocity to achieve the appropriate binding kinetics. Sample and detection reagent is bound to the column to complete the immunoassay. Overall this process rapid and accurate allowing detection of >100 samples in approximately 50 min [20] [21] [22] .
The ForteBio Octet™ system uses optical biosensors and biolayer interferometry to detect and quantify molecular interactions using disposable fiber optic biosensors. The biosensor's tips are coupled with various ligands [23] . For typical IgG determination, protein A biosensors are used, however there are a variety of ligands available in order to adapt the assay as needed (i.e., Protein G, Streptavidin, etc.). The biosensors are dipped into the samples and the analyte is bound to the ligand on the surface of the biosensor. That binding rate is measured by interferometry to determine product concentration. This binding event also provides data to measure the binding kinetics as well. ForteBio Octet™ systems come in a variety of options and have the ability of accommodating high-density microtiter plate formats. These systems also have the option of parallel processing of 96 biosensors simultaneously, which can provide results from 96 individual samples in approximately 2 min. Therefore the potential throughput of this benchtop automation system is future science group Review Keil comparable to that of the high-throughput immunoassays executed on a liquid handling platforms.
Once the high producing colonies have been identified, traditionally, the clones are manually harvested, adapted into suspension cultures in shake flasks, and manually passaged for approximately 3 months to evaluate cell line stability. The manual harvesting and passaging processes are labor intensive and the number of clones able to be passaged by a single scientist is a potential rate limiting step in clone evaluation. Through the use of liquid handling platforms the processes of clone harvesting and suspension culture passaging have been automated [2, 4, 19] . After high producing colonies are identified, the liquid handling system can harvest them into larger culture vessels, and after a few days of incubation these cultures are further expanded to suspension spin tube cultures. Spin tubes are 50 ml conical tubes with ventilated caps, and have been shown to be a comparable alternative to shake flask cultures [24, 25] . A Tecan Evo liquid handling platform has been modified to accommodate 96 spin tubes at a time and has the functionality to carry out culture sampling, media addition and culture passaging [17, 19] . Traditionally, a single scientist could passage approximately 96 cultures within an 8 h time frame comfortably; however with this automation workflow described above the at least a twofold increase in throughput is realized (Figure 3) , and the scientist can perform other tasks while this is running.
High-throughput microbioreactor screening & process development
One of the major bottlenecks in upstream clone selection and screening is the evaluation of these large numbers of clones in fed-batch cultures for productivity and critical quality attributes. This would require the scientist to perform a large number of fed-batch cultures in shake flasks, manually sampling and feeding them for the duration of the culture. Additionally, manual shake flask fed-batches cultures lack dOand pH monitoring as well as other process control strategies afforded by stirred-tank bioreactors. With the introduction of microscale bioreactors into the upstream cell line development workflow, this bottleneck has been alleviated.
The Sartorius (previously TAP Biosystems) AMBR™ microbioreactor system is a fully automated system that utilizes miniature single-use bioreactors that are 10-15 ml in working volume. This system is customizable to accommodate up to 48 bioreactors functioning simultaneously in parallel. Utilizing this system a single scientist can run 48-96 cultures easily with minimal user intervention. Additionally, the AMBR™ system has an integrated liquid handling arm for the sampling, removal and addition of liquids High-throughput screening & automation approaches for the development of recombinant therapeutic proteins Review and feeds to each of the bioreactors. The system is also equipped with the ability to individually monitor and control dO and pH for each of the bioreactors independently. The system has the option of being integrated with additional benchtop automation systems such as the Beckman Coulter Vicell XR™ or the Cedex Hi-Res™ for automated cell analysis as well. In reference to performance, the AMBR™ systemhas been shown to be very comparable to 2-l scale bioreactors (Table 1) , however the performance of cultures on the system is not comparable to shake flasks [26] [27] [28] [29] [30] . This system is optimal to use during initial clone evaluation, media development and initial process ranging studies, and is also critical in providing key information as to which clones are more suited for scale-up into larger-scale stirred-tank bioreactors. An alternative to the Sartorius AMBR™ microbioreactor system is the Pall Micro-24™ microreactor system. This system uses a single-use 24-well cassette that can accommodate 3-7 ml working volumes. Each individual well within the cassette is monitored and controlled for pH, dO and temperature simultaneously and independently. One of the key advantages of this system is that it offers the flexibility of culturing either mammalian or microbial cells, whereas the AMBR™ microbioreactor system is designed specifically for mammalian cell applications. This system has shown consistent results in terms of cell growth and process control and can serve as a scale-down model for initial clone evaluation workflows [31] [32] [33] [34] . One potential drawback of the Micro-24™ microreactor system is the lack of onboard liquid handling. This prevents the system from being fully automated, and requires the scientist to manually sample and feed the cultures. Overall, this system is a small benchtop microbioreactor system that provides a high-throughput approach for initial clonal evaluation, however, due to the lack of on board liquid handling, the Micro-24™ microreactor is not as versatile as the other bioreactor systems discussed in this review.
Sartorius (TAP Biosystems) has also developed the AMBR250™ bioreactor system as well. This system is a larger scale automated bioreactor system, 250 ml working volume, and was designed to closely mirror larger scale stirred-tank bioreactors. Many of the key features that have made the microscale AMBR™ system successful have been incorporated into this larger AMBR250™. In addition to having larger 250 ml vessels, the system offers the ability to individually control temperature, stirring speeds, dO and pH for each bioreactor. It also affords the ability perform to complex feeding strategies as well. This system is also unique in its design in that it can accommodate different varieties of bioreactors that can be used to culture mammalian cells, yeast cells or microbial cultures [18, 31, 35] . With all of these combined benefits, a single scientist is able to run anywhere from 24-48 reactors with minimal intervention. In comparison, if the same number glass 3-l bioreactors were to be ran, this would require an entire workforce of personnel to operate and maintain, therefore incurring much larger operating costs.
Conclusion
Implementation of automation technologies have led to improvements in all aspects of bioprocess development. The illustration shown in Figure 4 provides an example of how high-throughput methods and automation can be implemented and utilized for upstream bioprocess development, in particular production cell line development. Table 3 summarizes both the efficiency and screening capacity gained through the use of this automation within production cell line development. In addition, the approach taken here is modular allowing for the evolution of current technologies as well the potential integration of new and emerging technologies to improve workflows. These highthroughput automation solutions are able to provide significant advantages such as: reduced manual operation, ability to screen larger numbers of clones and/ or samples, better traceability and digital documentation, and reduction of human error. Together, these advantages accrued through high-throughput methods and automation lead to reduced project timelines, higher product yields, and a reduction in operating costs, which ultimately lead to a more productive and efficient bioprocess d evelopment organization. Table 2 . Culture performance of three separate production celllines in shake flask, AMBR™ microbioreactor and 2-l bioreactors. 
Future perspective
The use of recombinant therapeutic proteins has become increasingly more prevalent for the treatment of disease in recent years [36] , and as a result of the increased demand for these treatments, i mprovements in the development of recombinant therapeutic proteins is critical. In the past, one of the major focuses for the industry was to increase the overall productivity of the manufacturing cell lines. Over the years, protein production concentrations have significantly increased to grams per liter quantities (now considered at an acceptable level), and the paradigm of increasing the overall protein yield has been somewhat alleviated and shifted toward shortening development timelines [1, 3] . In addition to shortening development timelines, there has also been an increased focus on product quality characteristics. The pharmaceutical industry is currently interested in the implementation of process analytical tools for the analysis of both products and enhanced control of production processes [37] . These tools are being integrated in all aspects of upstream and downstream process development. The data generated using these tools will provide a greater understanding of the underlying biological processes and will allow for increased control over specific product quality requirements as well as more consistent overall protein production. In addition, there have been significant efforts in the field of continuous bioprocessing, which will require new process analytical tools to maintain production processes both upstream and downstream within very specific set criteria.
Therapeutic monoclonal antibody production has become a relatively well established process, and there has been a recent shift toward alternative antibody and non-antibody formats. These new therapeutic protein formats present challenges in terms of adapting the current screening strategies and analytical techniques to accurately identify and characterize these new modalities. In the future, therapeutic protein manufacturers will require ability to develop both 'standard' therapeutic monoclonal antibodies as well as 'nonstandard' therapeutic protein modalities. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
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